Study about Cryopyrin-Associated Periodic Syndromes (CAPS)
Abstract: Few medical communication reports discuss the planning and execution of clinical publications that describe treatment options for rare or “orphan” diseases. While orphan-designated drugs follow the same development pathway as ther pharmaceutical products, key challenges are the limited resources and small patient pools available for research, thus often restricting the number of scientiﬁc studies and associated publications.
Physician-driven disease-state/ educational publications therefore increasingly become important in highlighting the unmet needs of 1such patient populations. This report describes publication activity in support of rilonacept, an orphan-designated drug for a rare disorder, Cryopyrin-Associated Periodic Syndromes (CAPS). Keep reading…
This paper examines from various angles the complex relationship between intellectual-property rights and technological innovation. Part I summarizes the principal economic theories concerning how intellectual-property systems can stimulate or impede technological progress. Part II discusses the extent to which those theories find support in the histories in the United States of four technology-intensive industries: pharmaceutical products; biotechnology; aviation; and computer software. The Conclusion attempts to extract from those four historical case studies some generalizations concerning when and how intellectual-property rights might sensibly be employed to foster innovation.
We begin with some familiar generalizations: Technological innovations belong to the category of objects and services that economists refer to as “public goods.” The distinctive characteristics of public goods are that they can be replicated easily and that they are “nonrivalrous” – in other works, enjoyment of them by one person does not prevent enjoyment of them by other persons. Those characteristics in combination create a danger that the pace of technological innovation will fall below socially optimal levels. Why? Because potential innovators will know that, once they reveal their breakthroughs to the world, other people will be able to take advantage of them for free. Keep reading..
Case Study about Pharmaceutical Price Controls in OECD Countries
Executive Summary: Improvements in health care and life sciences are an important source of gains in health and longevity globally. The development of innovative pharmaceutical products plays a critical role in ensuring these continued gains. To encourage the continued development of new drugs, economic incentives are essential. These incentives are principally provided through direct and indirect government funding, intellectual property laws, and other policies that favor innovation. Without such incentives, private corporations, which bring to market the vast majority of new drugs, would be less able to assume the risks and costs necessary to continue their research and development (R&D).
The study examined the drug price regulatory systems of 11 OECD countries and found that all rely on some form of price controls to limit spending on pharmaceuticals. The principal methods these governments employ are reference pricing, approval delays and procedural barriers, restrictions on dispensing and prescribing, and reimbursement. These methods prevent companies from charging a market-based price for their products. They also tend to be nontransparent, as the criteria and rationale for certain pharmaceutical prices or reimbursement amounts are not fully disclosed even to the pharmaceutical companies seeking to market their drugs.
Wakefield-based Boston Healthcare received £1.25 million investment from Finance Yorkshire’s Equity Fund.The company, which was established in April 2010, will use the investment to procure, market and distribute a range of well-known pharmaceutical products. The portfolio of over-the-counter (OTC) products produced by Boston Healthcare includes a range of sun protection products and multi-vitamins already available in high street retailers and pharmacies..
Click here to read more on Boston Healthcare
Quadrant Capital acquired Penrice from Champ in May 2004. Penrice was the sole manufacturer of soda ash and sodium bicarbonate in Australia and supplied 74% of the soda ash and 88% of sodium bicarbonate in Australia. It also operated the largest marble and limestone mine in South Australia. Soda ash is predominantly sold into the Australian market for use in the manufacture of glass containers and flat glass. Sodium bicarbonate is sold domestically as well as exported with major end uses including animal feed, food, kidney dialysis, personal care and pharmaceutical products. Find out more about Penrice Soda Holdings Limited
A Holistic Egyptian InitiativeSummary: In 1977, the Sekem initiative was founded by Dr. Ibrahim Abouleish to support the development of the individual, society and the earth, through the initiative’s various economic, social and cultural activities. Sekem’s group includes eight companies: Libra for farming, Mizan for organic seedlings, Hator for fresh fruits and vegetables, Lotus for herbs and spices, Isis for organic foods and beverages (such as bread, dairy products, oils, spices and tea), Conytex for organic cotton and textile fabrics, Atos for pharmaceutical products, and Ecoprofit (under establishment) for sustainable management.
Introduction: Having lived for 21 years in Austria, Ibrahim Abouleish decided to return to Egypt. Abouleish, founder and chairman of Sekem Group in Egypt, could not stop thinking about images and events of his previous visit to his home country. “During my trip I had become aware of the excessive use of artificial fertilizer, and I discovered far worse things about Egypt’s economy, education and health situation and agriculture and trade relations than I had already learned through my discussions with Egyptians,” said Abouleish. In an effort to help eradicate poverty and to contribute to the advancement of the individual. Click here to read more…
With a large team of scientists on staff, many scientific reports are written at Acrux. This dynamic Australian drug delivery company is in the business of developing and commercialising a range of patient-preferred pharmaceutical products. Their product development and formulation reports are critical components of the folios presented to potential customers and regulatory bodies. These reports have to convince the reader that the products work as stated, with sound scientific evidence to support therapeutic claims. Click here to read more…